BioCentury
ARTICLE | Clinical News

Aloxi palonosetron: Phase III data; marketed

January 5, 2004 8:00 AM UTC

Subset analysis from 2 previously reported Phase III trials showed that in 695 patients with breast cancer, 50% of those treated with Aloxi had a complete response during the 0-120 hour period compare...